Impact of travel burden on clinical outcomes in lung cancer
- PMID: 35288785
- DOI: 10.1007/s00520-022-06978-8
Impact of travel burden on clinical outcomes in lung cancer
Abstract
Purpose: Our study explores the influence of travel burden (measured as travel distance and travel time) on clinical outcomes in lung cancer patients.
Methods: A retrospective analysis of a single Bulgarian center was performed. A total of 9240 lung cancer patients were included in the study. Travel distance and travel time between patients' city of residence and the treating facility were calculated with an online tool to determine the shortest route for travel using the existing road network. The probability of survival was estimated using the Kaplan-Meier method, and differences in survival in each subgroup were evaluated with a log-rank test.
Results: About one third of all included patients were living in the same city as the treating facility (n = 2746, 29.7%). Overall survival in our patient population was significantly lower with increasing travel distance (p < 0.001, Mantel-Cox log rank) and travel time (p < 0.001, Mantel-Cox log rank). The 1-year OS rate according to travel distance was 27.1% in the same city group, 22.4% in < 50-km group, and 20.5% in ≥ 50-km group (p < 0.001). The corresponding values for the 5-year OS rate were 2.9%, 2.6%, and 1.4% (p < 0.001).
Conclusion: In this retrospective study, we discovered significant differences in the overall survival of patients with lung cancer depending on travel distance and travel time to the treating oncological facility. Despite having similar clinical and pathological characteristics (age, sex, stage at initial diagnosis, histologic subtype), the median overall survival was significantly lower in those subgroups of patients with a higher travel burden.
Keywords: Clinical outcomes; Lung cancer; Overall survival; Travel burden; Travel distance.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clinic 71(3):209–249. https://doi.org/10.3322/caac.21660
-
- Freeman RK, Van Woerkom JM, Vyverberg A, Ascioti AJ (2010) The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. Eur J Cardiothorac Surg 38(1):1–5. https://doi.org/10.1016/j.ejcts.2010.01.051 - DOI - PubMed
-
- Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB, Meropol NJ (2009) Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol 27(28):4671. https://doi.org/10.1200/jco.2008.20.1715 - DOI - PubMed - PMC
-
- Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH (2014) Gynecologic cancer disparities: a report from the health disparities taskforce of the society of gynecologic oncology. Gynecol Oncol 133(2):353–361. https://doi.org/10.1016/j.ygyno.2013.12.039 - DOI - PubMed - PMC
-
- Lisovicz N, Wynn T, Fouad M, Partridge EE (2008) Cancer health disparities: what we have done. Am J Med Sci 335(4):254. https://doi.org/10.1097/maj.0b013e31816a43ad - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
